Skip to main content

Long COVID Revitalize study

By
This study is a Phase III, double-blind, placebo-controlled, multi-arm platform study that will enroll participants from Brasil, Canada, Italy, Uganda, Zambia, and the United States. The first phase, involving 348…
Read More

SPARKLE

By
Crizanlizumab is a potent and selective IgG2 (immunoglobulin G2) kappa humanized monoclonal antibody that binds to human P-selectin with high affinity, blocking its interaction with its ligands, including P-selectin glycoprotein…
Read More

TIMING

By
Amendment: The role of Trained Immunity and Mitochondrial dysfunction on INnate immunity in children and adolescents aGing with PHIV (TIMING-PHIV)’ Description: The impact of inflammation on non-AIDS co-morbidities in children…
Read More

HIBISCUS

By
The combination of anti-sickling effects, decreased haemolysis and improved red blood cell (RBC) membrane integrity due to etavopivat treatment is proposed to improve RBC health and reduce the onset and…
Read More

OTAC

By
Outpatient Treatment with Anti-Coronavirus Immunoglobulin (OTAC) (INSIGHT 012) Coronavirus disease 2019 (COVID-19) is a predominantly respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and causes substantial morbidity…
Read More

MUTIMA STUDY

By
Preliminary data suggests a probable effect of HIV on myocardial fibrosis and steatosis in women, with inflammation being a key driver of fibrosis and metabolic dysfunction. The primary objective of…
Read More
Close Menu